Cardiac Biomarker Diagnostic Kits Market Size, Share, Growth, Trends, Revenue, Consumption, Company Analysis and Forecast 2020-2027

The global cardiac biomarker diagnostic kits market size surpassed US$ 2,180 million in 2019. It is anticipated to reach US$ 3,500 million by 2027, expanding at a CAGR of 5.8% from 2020 to 2027.

Chest pain is a common emergency department (ED) presentation accounting for 8-10 million visits per year in the U.S. The increasing number of patient visits in the emergency department is expected to create growth opportunities for the cardiac biomarker diagnostic test kits market. Obesity has become a global health challenge in the past few decades, with every sixth person being obese. According to the WHO, the number of obese population around the globe has doubled in the last two decades. The growing obese population, which is at a high risk of developing cardiovascular diseases, is expected to consequently increase the demand for cardiac biomarker diagnostic test kits. Moreover, the leading manufacturers of cardiac biomarker diagnostic test kits are focusing on collaborating with universities and associations to develop and expand their product portfolio. On the other hand, less availability of novel cardiac biomarker diagnostic test kits due to tedious approval procedures is expected to hamper the growth of the cardiac biomarker diagnostic test kits market over the next decade.

Overview

  • Cardiac biomarkers are also called cardiac markers. In a condition when the heart is damaged or stressed, cardiac biomarkers (endogenous substances including enzymes, hormones, and proteins) are released into the blood.
  • Generally, cardiac markers are used to diagnose heart attack and acute coronary syndrome (ACS) or conditions associated with insufficient blood flow to the heart. These markers are also utilized in the diagnosis and risk stratification of patients with chest pain.
  • Among cardiac biomarker tests, troponin is the biomarker test of choice for detecting heart damage. The test is performed with a blood sample using a needle to draw blood from a vein in the hand or arm. Troponin is elevated within a few hours of heart damage and stays elevated up to two weeks.
  • There are other established biomarkers, such as myoglobin (test used along with troponin for early detection of heart attack) and creatinine kinase isoenzymes (also called cardiac enzyme, which is linked with injury of heart muscle and detection of a second heart attack anticipated shortly after the first)

Rise in prevalence of cardiovascular diseases across the world to Drive Market

  • Growing prevalence of cardiovascular diseases across the world is the major driver for the growth of global cardiac biomarker diagnostic kits market.
  • For instance, the American Heart Association estimated that 121.5 million adults had cardiovascular diseases between 2013 and 2016
  • Advancements in novel technologies and increasing government funding for cardiovascular disease treatment are some of the major factors responsible for the growth of global cardiac biomarker diagnostic kits market
  • Moreover, early detection to track the heart condition and integration of cardiology & IT are also some of the major factors fuelling the growth of global cardiac biomarker diagnostic kits market

Troponin Test Kits Segment to Dominate Market

  • Based on product, the global cardiac biomarker diagnostic kits market has been segmented into troponin test kits, CK-MB test kits, myoglobin test kits, BNP test kits, C-reactive Protein (hsCRP), and other biomarkers
  • Troponin test kits segment is accounted for major market share in global cardiac biomarker diagnostic kits market in 2018
  • Growth of troponin test kits segment can be ascribed to its prodigious specificity and ability to accurately detect the cardiac events of acute coronary syndrome (ACS).

Cardiac Heart Failure – Promising Application Segment

  • In terms of application, the global cardiac biomarker diagnostic kits market has been divided into angina pectoris, myocardial infarction (MI), cardiac heart failure, and others
  • Angina pectoris dominated the global market in 2018 and is projected to dominate by the end of 2027 due to high incidence rate of angina pectoris across the globe
  • Cardiac heart failure is more lucrative segment during the forecast period which is growing with a higher CAGR during the same period of 2019-2027 owing to rise in number of patient cases for cardiac heart failure across the world

Pont-of-care testing Segment– Higher Growth Rate

  • On the basis of testing, the global cardiac biomarker diagnostic kits market has been bifurcated into laboratory testing, and point-of-care testing
  • Point-of-care testing is more promising segment which is expected to grow with higher CAGR during the forecast period.
  • Easy accessibility of point-of-care testing, increase in preference for point-of-care testing, and new kits & assays being offered by market players for rapid tests are expected to drive the point-of-care testing segment during the forecast period.

Diagnostic Laboratory End-user Segment- Major Market Share

  • Based on end-user, the global cardiac biomarker diagnostic kits market has been segmented into hospitals, clinics, and diagnostic laboratory
  • Diagnostic laboratory segment dominated the global cardiac biomarker diagnostic kits market in 2018 due to rise in hospital admissions for dental procedures, favorable reimbursement scenario, and increase in number of advanced diagnostic laboratories in the last decade which has led to a higher number of diagnostic tests being performed at these settings

North America to Dominate Global Market

  • In terms of region, the global cardiac biomarker diagnostic kits market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
  • North America accounted for major share of the global cardiac biomarker diagnostic kits market in 2018 due to higher cardiovascular disease patient population, significant average selling price of analyzers, rise in demand for technologically advanced diagnostic instruments with enhanced specificity and precision among cardiologist, and favorable coverage as per the Clinical Laboratory Improvement Amendments for in-vitro diagnostic procedures in the region
  • For instance, an article published in the Medscape states that more than 9.8 million people in the U.S. experience symptoms of angina, annually, and more than 500,000 cases are registered every year
  • The cardiac biomarker diagnostic kits market in Asia Pacific is anticipated to expand at a high CAGR from 2019 to 2027. This can be ascribed to growing aging population, developing health care infrastructure, large patient population, increase in funding and investment toward the development of cardiac analyzers, and surge in focus of both international and domestic players in the region.

The report analyzes and forecasts the cardiac biomarker diagnostic kit market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.

The report comprises a detailed value chain analysis, which provides a comprehensive view of the global cardiac biomarker diagnostic kit market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view of the cardiac biomarker diagnostic kit market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The report provides size (in terms of volume and value) of cardiac biomarker diagnostic kit market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

Companies Mentioned in the Report

The report profiles major players operating in the global Cardiac Biomarker Diagnostic Kits market in terms of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in this report include Abbott Laboratories, Hoffmann-La Roche AG, Bio-Rad Laboratories, Danaher Corporation, Seimens Healthineers, Thermofisher Scientific, bioMérieux, Randox Laboratories Ltd., and Ortho Clinical Diagnostics. 

Market Segmentation

By Disease Indication

  • Angina pectoris
  • Myocardial Infraction (MI)
  • Cardiac Heart Failure
  • Others

By Product

  • Troponin Test Kits
  • CK-MB Test Kits
  • Myoglobin Test Kits
  • BNP Test Kit
  • C-reactive Protein (hsCRP)
  • Other Biomarkers (galectin-3, H-FABP, myeloperoxidase, ischemia-modified albumin, and homocysteine)

By Testing

  • Laboratory Testing
  • Pont-of-care Testing

By End-user

  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Others

By Region

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • U.K
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia & New Zealand
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Reasons to Purchase this Report:

- Estimates 2019-2026 cardiac biomarker diagnostic kit market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.

Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.

The study objectives of this report are:

  • To analyze and study the global cardiac biomarker diagnostic kit capacity, production, value, consumption, status (2014-2018) and forecast (2019-2026);
  • Focuses on the key cardiac biomarker diagnostic kit manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
  • To define, describe and forecast the market by type, application and region.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

CHAPTER 1. Preface
1.1. Definition and Scope
1.2. Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

CHAPTER 2. Assumptions and Research Methodology

CHAPTER 3. Executive Summary : Global Market

CHAPTER 4. Overview
4.1. Introduction
4.1.1. Products Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Market Analysis and Forecast, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

CHAPTER 5. Market Key Insights
5.1. Regulatory Scenario by Region/Globally
5.2. Key Mergers & Acquisitions
5.3. Reimbursement Scenario
5.4. Cardiac Diseases Prevalence Rate Globally with Key Countries
5.5. Top 3 players operating in the market space

CHAPTER 6. Global Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Market Value Forecast, by Product, 2016–2026
6.3.1. Troponin Test Kits
6.3.2. CK-MB Test Kits
6.3.3. Myoglobin Test Kits
6.3.4. BNP Test Kit
6.3.5. C-reactive Protein (hsCRP)
6.3.6. Others
6.4. Global Market Attractiveness, by Product

7. Global Market Analysis and Forecast, by Testing
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Market Value Forecast, by Testing, 2016–2026
7.3.1. Laboratory Testing
7.3.2. Pont-of-care Testing
7.4. Global Market Attractiveness, by Testing

8. Global Market Analysis and Forecast, by Disease Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Market Value Forecast, by Disease Indication, 2016–2026
8.3.1. AngiStent Type Pectoris
8.3.2. Myocardial Infraction
8.3.3. Cardiac Heart Failure
8.3.4. Other
8.4. Global Market Attractiveness, by Disease Indication

9. Global Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Global Market Value Forecast, by End-user, 2016–2026
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Diagnostic Laboratory
9.3.4. Others
9.4. Global Market Attractiveness, by End-user

10. Global Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Global Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Market Attractiveness, by Region

11. North America Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. North America Market Value Forecast, by Product, 2016–2026
11.2.1. Troponin Test Kits
11.2.2. CK-MB Test Kits
11.2.3. Myoglobin Test Kits
11.2.4. BNP Test Kit
11.2.5. C-reactive Protein (hsCRP)
11.2.6. Others
11.3. North America Market Value Forecast, by Testing, 2016–2026
11.3.1. Laboratory Testing
11.3.2. Pont-of-care Testing
11.4. North America Market Value Forecast, by Disease Indication, 2016–2026
11.4.1. AngiStent Type Pectoris
11.4.2. Myocardial Infraction
11.4.3. Cardiac Heart Failure
11.4.4. Other
11.5. North America Market Value Forecast, by End-user, 2016–2026
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Diagnostic Laboratory
11.5.4. Others
11.6. North America Market Value Forecast, by Country, 2016–2026
11.6.1. U.S.
11.6.2. Canada
11.7. North America Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Testing
11.7.3. By Disease Indication
11.7.4. By End-user
11.7.5. By Country

12. Europe Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Europe Market Value Forecast, by Product, 2016–2026
12.2.1. Troponin Test Kits
12.2.2. CK-MB Test Kits
12.2.3. Myoglobin Test Kits
12.2.4. BNP Test Kit
12.2.5. C-reactive Protein (hsCRP)
12.2.6. Others
12.3. Europe Market Value Forecast, by Testing, 2016–2026
12.3.1. Laboratory Testing
12.3.2. Pont-of-care Testing
12.4. Europe Market Value Forecast, by Disease Indication, 2016–2026
12.4.1. AngiStent Type Pectoris
12.4.2. Myocardial Infraction
12.4.3. Cardiac Heart Failure
12.4.4. Other
12.5. Europe Market Value Forecast, by End-user, 2016–2026
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Diagnostic Laboratory
12.5.4. Others
12.6. Europe Market Value Forecast, by Country/Sub-region, 2016–2026
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Testing
12.7.3. by Disease Indication
12.7.4. by End-user
12.7.5. by Country/Sub-region

13. Asia Pacific Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Asia Pacific Market Value Forecast, by Product, 2016–2026
13.2.1. Troponin Test Kits
13.2.2. CK-MB Test Kits
13.2.3. Myoglobin Test Kits
13.2.4. BNP Test Kit
13.2.5. C-reactive Protein (hsCRP)
13.2.6. Others
13.3. Asia Pacific Market Value Forecast, by Testing, 2016–2026
13.3.1. Laboratory Testing
13.3.2. Pont-of-care Testing
13.4. Asia Pacific Market Value Forecast, by Disease Indication, 2016–2026
13.4.1. AngiStent Type Pectoris
13.4.2. Myocardial Infraction
13.4.3. Cardiac Heart Failure
13.4.4. Other
13.5. Asia Pacific Market Value Forecast, by End-user, 2016–2026
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Diagnostic Laboratory
13.5.4. Others
13.6. Asia Pacific Market Value Forecast, by Country/Sub-region, 2016–2026
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia Pacific Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Testing
13.7.3. By Disease Indication
13.7.4. By End-user
13.7.5. By Country/Sub-region

14. Latin America Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Latin America Market Value Forecast, by Product, 2016–2026
14.2.1. Troponin Test Kits
14.2.2. CK-MB Test Kits
14.2.3. Myoglobin Test Kits
14.2.4. BNP Test Kit
14.2.5. C-reactive Protein (hsCRP)
14.2.6. Others
14.3. Latin America Market Value Forecast, by Testing, 2016–2026
14.3.1. Laboratory Testing
14.3.2. Pont-of-care Testing
14.4. Latin America Market Value Forecast, by Disease Indication, 2016–2026
14.4.1. AngiStent Type Pectoris
14.4.2. Myocardial Infraction
14.4.3. Cardiac Heart Failure
14.4.4. Other
14.5. Latin America Market Value Forecast, by End-user, 2016–2026
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Diagnostic Laboratory
14.5.4. Others
14.6. Latin America Market Value Forecast, by Country/Sub-region, 2016–2026
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Latin America Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Testing
14.7.3. By Disease Indication
14.7.4. By End-user
14.7.5. By Country/Sub-region

15. Middle East & Africa Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Middle East & Africa Market Value Forecast, by Product, 2016–2026
15.2.1. Troponin Test Kits
15.2.2. CK-MB Test Kits
15.2.3. Myoglobin Test Kits
15.2.4. BNP Test Kit
15.2.5. C-reactive Protein (hsCRP)
15.2.6. Others
15.3. Middle East & Africa Market Value Forecast, by Testing, 2016–2026
15.3.1. Laboratory Testing
15.3.2. Pont-of-care Testing
15.4. Middle East & Africa Market Value Forecast, by Disease Indication, 2016–2026
15.4.1. AngiStent Type Pectoris
15.4.2. Myocardial Infraction
15.4.3. Cardiac Heart Failure
15.4.4. Other
15.5. Middle East & Africa Market Value Forecast, by End-user, 2016–2026
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Diagnostic Laboratory
15.5.4. Others
15.6. Middle East & Africa Market Value Forecast, by Country/Sub-region, 2016–2026
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Middle East & Africa Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Testing
15.7.3. By Disease Indication
15.7.4. By End-user
15.7.5. By Country/Sub-region

16. Competition Landscape
16.1. Market Player – Competition Matrix (by Tier and Size of companies)
16.2. Market Share Analysis by Company (2017)
16.3. Competitive Business Strategies
16.4. Company Profiles
16.4.1. Abbott Laboratories Ltd.
16.4.1.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.1.2. Business Overview
16.4.1.3. Product Portfolio
16.4.1.4. Financial Overview
16.4.1.5. SWOT Analysis
16.4.2. Hoffmann-La Roche AG
16.4.2.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.2.2. Business Overview
16.4.2.3. Product Portfolio
16.4.2.4. Financial Overview
16.4.2.5. SWOT Analysis
16.4.3. Bio-Rad Laboratories
16.4.3.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.3.2. Business Overview
16.4.3.3. Product Portfolio
16.4.3.4. Financial Overview
16.4.3.5. SWOT Analysis
16.4.4. Danaher Corporation
16.4.4.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.4.2. Business Overview
16.4.4.3. Product Portfolio
16.4.4.4. Financial Overview
16.4.4.5. SWOT Analysis
16.4.5. Seimens Healthineers
16.4.5.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.5.2. Business Overview
16.4.5.3. Product Portfolio
16.4.5.4. Financial Overview
16.4.5.5. SWOT Analysis
16.4.6. Thermofisher Scientific
16.4.6.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.6.2. Business Overview
16.4.6.3. Product Portfolio
16.4.6.4. Financial Overview
16.4.6.5. SWOT Analysis
16.4.7. bioMérieux
16.4.7.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.7.2. Business Overview
16.4.7.3. Product Portfolio
16.4.7.4. Financial Overview
16.4.7.5. SWOT Analysis
16.4.8. Ortho Clinical Diagnostics
16.4.8.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.8.2. Business Overview
16.4.8.3. Product Portfolio
16.4.8.4. Financial Overview
16.4.8.5. SWOT Analysis

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers